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substrate preferences, enzyme kinetics, cellular and organ-
elle locations, and regulation. ACSL4 has a marked 
preference for 20:4 (arachidonic acid, AA) and 20:5 (ei-
cosapentaenoic acid). The high affi nity of ACSL4 for these 
fatty acids and the low affi nity for palmitic acid suggest 
that the enzyme plays a key role in the metabolism of AA. 
A second interesting feature of ACSL4 is its tissue distribu-
tion. In rats, its mRNA is expressed in various tissues, in-
cluding the adrenal gland, epididymis, brain, lung, ovary, 
placenta, liver, and testis ( 6, 7 ). The striking feature of 
ACSL4 is its abundance in steroidogenic tissues, especially 
in  zona fasciculata and  reticularis of the rat adrenal gland, 
Leydig cells of the testis, and luteinized cells of the ovary 
( 7 ). It is interesting that although relatively low or null ex-
pression levels of ACSL4 have been reported in other adult 
tissues ( 6, 7 ), this isoform is overexpressed in breast, pros-
tate, colon, and liver cancer specimens ( 8–10 ). 
 Regarding its function ,  ACSL4 is related to the acute 
regulation of steroid production in steroidogenic tissues. 
ACSL4 is a key protein ( 11 ) that works in concert with a 
mitochondrial acyl-CoA thioesterase, ACOT2 ( 12, 13 ). 
These two fatty acid-metabolizing enzymes constitute an 
AA generation/export system, which releases AA in the 
mitochondrion after the action of the steroidogenic hor-
mones  adrenocorticotropin hormone (ACTH) and  luteiniz-
ing hormone (LH)/ chorionic gonadotropin (CG) ( 14 ). 
AA is then metabolized to lipoxygenated or epoxygen-
ated products to induce the expression of the  ste-
roidogenesis acute regulatory (StAR) gene. StAR is a 
mitochondrial protein that, together with other proteins, 
participates in cholesterol transport to the inner mito-
chondrial membrane, which constitutes the rate-limiting 
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 Because of this background, we postulate that SHP2 could 
be the tyrosine phosphatase necessary for ACSL4 protein in-
duction. The aim of  this study was to analyze the involve-
ment of SHP2 in the regulation of ACSL4 protein levels. 
Here, we introduce the notion that there are SHP2
-determined high levels of ACSL4 protein in MDA-MB231 
cells and that SHP2 action stimulates proliferation of these 
cultured breast cancer cells. In addition, using plasmid-
mediated gene transfer and RNAi-mediated gene silencing, 
we provide evidence for the fi rst time that SHP2 has an oblig-
atory role in steroid production by MA-10 cells, a mouse Ley-
dig cell line, regulating the expression of ACSL4 protein, the 
rate-limiting enzyme in the AA generation/export system. 
 MATERIALS AND METHODS 
 Reagents 
 8Br-cAMP, arachidonic acid (AA), BSA, essentially free-fatty 
acid BSA, collagenase, Waymouth MB/752, 3-(4,5-dimethylthi-
azol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), and pheny-
larsine oxide (PAO) were obtained from Sigma Chemical Co. 
Horse serum, DMEM, Medium 199, trypsin-EDTA, penicillin-
streptomycin, and Lipofectamine 2000 were purchased from 
GIBCO-Invitrogen. FBS was obtained from PAA Laboratories. Bis-
acetoxymethyl ester (AM) derivative of benzylphosphonic acid 
(BPA) [benzylphosphonic acid-(AM) 2 , (BPA-(AM) 2 )] was pur-
chased from BIOMOL International, and 8-hydroxy-7-[(6-sulfo-2-
naphthyl)azo]5-quinolinesulfonic acid (NSC87877) from Tocris 
Bioscience International. PVDF membrane, goat anti-rabbit, and 
anti-mouse IgG secondary antibody conjugated with horseradish 
peroxidase were obtained from Bio-Rad. Sterile and plastic mate-
rial for tissue culture was from Orange Scientifi c. All other chemi-
cals used in this study were of highest possible quality. 
 Cell cultures 
 MA-10 mouse Leydig tumor cells were generously provided by 
Dr. Mario Ascoli (University of Iowa, Iowa City, IA) and cultured 
in Waymouth MB/752 medium supplemented with 15% horse 
serum and antibiotics at 37°C and 5% CO 2 as previously de-
scribed ( 31 ). The culture medium was replaced with serum-free 
Waymouth medium before experiments. 
 The human breast cancer cell line MDA-MB-231 was generously 
provided by Dr. Vasilios Papadopoulos (Research Institute of the 
McGill University Health Centre, Montreal, Canada) and obtained 
from the Lombardi Comprehensive Cancer Center (Georgetown 
University Medical Center, Washington, DC). The cell line was 
maintained in DMEM medium supplemented with 10% FBS and 
antibiotics at 37°C and 5% CO 2 as previously described ( 17 ). 
 Interstitial testicular cells were obtained from adult Wistar 
male rats. The animals were purchased from the animal facility of 
the School of Pharmacy and Biochemistry, University of Buenos 
Aires. The studies were approved by the Institutional Committee 
for the Care and Use of Laboratory Animals (CICUAL) of the 
School of Medicine, University of Buenos Aires. Freshly isolated 
interstitial cells were prepared by collagenase dispersion of testes 
as previously described ( 32 ). Cells were resuspended in Medium 
199 containing 1.2 g/l NaHCO 3 , and 0·5% BSA, at a density of 
10 6 cells/ml and were maintained under a carbogen (95% O 2 :5% 
CO 2 ) atmosphere throughout the procedures. 
 Plasmids and sequences 
 Mammalian expression vectors encoding the wild-type and the 
catalytically inactive SHP2 mutant, Addgene plasmids 8381 and 
step of the steroidogenic biosynthetic pathway. Regarding 
the function of ACSL4 in other cell types, sustained down-
regulation of ACSL4 results in markedly reduced PGE2 
release in human arterial smooth muscular cells ( 15 ), indi-
cating that endogenous ACSL4 plays an important role as 
a regulator of eicosanoid synthesis and secretion, which 
might regulate smooth muscle cell proliferation, release 
of infl ammatory mediators, or other processes in the vas-
cular wall ( 15 ). ACSL4 also contributes to the development 
of human hepatocellular carcinoma, adenocarcinoma, 
and breast cancer ( 9, 10, 16, 17 ). ACSL4 is signifi cantly 
upregulated in highly aggressive breast cancer cell lines 
( 10, 17 ). The effect of ACSL4 on cell proliferation, inva-
sion, and migration is attributed to increased production 
of lipoxygenase and cycloxygenase metabolites ( 17 ), which 
are known to potentiate tumor aggressiveness in hepato-
cellular carcinoma ( 8 ), colon adenocarcinoma ( 9 ), and 
breast cancer ( 10, 17 ).  In summary, differences in the 
abundance and/or activity of ACSL4 may result in varia-
tions in the cellular content of free AA and AA-CoA, as 
well as in lipoxygenated and cycloxygenated metabolites. 
These compounds in turn play critical roles in steroid pro-
duction in steroidogenic systems and in cell proliferation, 
migration, and invasion in cancer progression. 
 The cAMP-dependent action of ACTH and LH/CG on 
ACSL4 described above is mediated by the activity of pro-
tein tyrosine phosphatases (PTP) ( 18 ). The use of com-
pounds that inhibit PTP enzymatic activity results in a 
decrease in cAMP-stimulated ACSL4 protein levels, in 
cAMP-stimulated steroid production ( 19–22 ), and in cAMP-
stimulated tyrosine dephosphorylation of paxillin and focal 
adhesion disassembly ( 23 ). Although cAMP-dependent 
stimulation of steroidogenic cells increases the activity of 
several PTPs, the PTP(s) responsible for the increase in 
ACSL4 protein levels and steroid production is (are) still 
not identifi ed. In this work, we focused on an 80 kDa hor-
mone-activated PTP recognized by commercially available 
antibodies against  src homology 2-containing phospho-
tyrosine phosphatase 2 ( SHP2), a member of the nonrecep-
tor PTP subfamily. In addition,  SHP2 is phosphorylated 
in vitro by cAMP-dependent protein kinase (PKA) and in vivo 
by ACTH in bovine adrenal cells ( 24 ). In both cases, phos-
phorylation increases SHP2 activity. However, no evidence 
is available on the relationship between this activation and 
the steroidogenic function of the cell. SHP2 is an ubiqui-
tously expressed nontransmembrane PTP that plays an es-
sential role in many organisms, from lower eukaryotes to 
mammals ( 25, 26 ). Interestingly, SHP2 is one of the PTPs 
that promote the activation, rather than the downregula-
tion, of intracellular signaling pathways ( 27, 28 ), serving 
multiple hormone receptors and participating in the regu-
lation of mitogenic signaling, cell adhesion, and cell migra-
tion ( 28 ). In addition, accumulating evidence suggests that 
SHP2 might play a pivotal role in carcinogenesis. It is up-
regulated in breast cancer cells and in approximately 70% 
of infi ltrating ductal carcinoma of the human breast, imply-
ing its involvement in breast oncogenesis ( 29 ). In contrast, 
inhibition of this PTP leads to reversion from mesenchymal 
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cells) were pretreated with or without NSC87877 (50 µM) for 30 min 
and then incubated in the presence or absence of 8Br-cAMP 
0.5 mM for 3 h at 37°C with gentle shaking. Testosterone produc-
tion was determined in the incubation media by RIA ( 21 ). At the 
end of all experiments, MA-10, MDA-MB-231, and testicular in-
terstitial cellular protein content were assayed by the Bradford 
method using BSA as standard ( 34 ). 
 PTP assay 
 SHP2 PTP activity was monitored by an in-gel PTP assay using 
[ 32 P]poly(Glu:Tyr) as substrate, with minor modifi cations ( 21 ) of 
the original description ( 35 ). Proteins exhibiting PTP activity are 
visualized as clear bands on a dark background due to removal of 
inorganic [ 32 P]phosphate from the radiolabeled substrate incor-
porated into the matrix gel ( 21, 35, 36 ). 
 Western blotting 
 SHP2 and ACSL4 protein levels were analyzed in a total cell 
lysate, and StAR protein levels were analyzed in the mitochon-
drial fraction. The primary antibodies used were purifi ed mono-
clonal mouse antibody anti-SHP2 (BD-transduction laboratories), 
polyclonal rabbit antibody anti-ACSL4 ( 13, 37 ) (obtained at our 
laboratory), rabbit antisera anti-StAR (generously provided by 
Dr. Doug Stocco), anti-  -tubulin (used as cell lysate loading con-
trol, Millipore), and anti-Ox-Phos complex III core 2 subunit 
(used as mitochondrial loading control, Invitrogen). The sec-
ondary antibodies were goat anti-mouse or goat anti-rabbit 
immunoglobulins (according to the primary antibody used) 
conjugated to peroxidase. The bound primary antibodies were 
detected using an enhanced chemiluminescence kit (GE Health-
care). The levels of SHP2, ACSL4, StAR,   -tubulin, and complex III 
were quantitated using a computer-assisted image analyzer (Im-
ageQuant 5.2), and the results for each sample were normalized 
by   -tubulin or complex III. 
 RNA extraction and semiquantitative RT-PCR 
 Total RNA from the different treatment groups was extracted 
using TriReagent following the manufacturer’s instructions 
(MRC, Inc.). The reverse transcription and PCR analyses were 
made using 2 µg of total RNA. The cDNAs generated were fur-
ther amplifi ed by PCR under optimized conditions using the 
primer pairs below. For amplifi cation of  Acsl4 (amplicon size 
420 bp), the sense primer, 5 ′ -GCCCACTTCAGACAAACCTGG-3 ′ , 
and the antisense primer, 5 ′ -ACAGCTTCTCTGCCAAGTGTGG-3 ′ , 
were used. For amplifi cation of  StAR (amplicon size 566 bp), the 
sense primer, 5 ′ -GGGACGAAGTGCTAAGTAAGATGG-3 ′ , and 
the antisense primer, 5 ′ -GGTCAATGTGGTGGACAGTCC-3 ′ , 
were used. For amplifi cation of  L19 ribosomal protein, used as 
housekeeping gene (amplicon size 405 bp), the sense primer, 
5 ′ -GAAATCGCCAATGCCAACTC-3 ′ , and the antisense primer, 
5 ′ -TCTTAGACCTGCGAGCCTCA-3 ′ ( 38 ) were used. The reac-
tion conditions were as follows: for  Acsl4 and  L19 , one cycle of 
94°C for 5 min, followed by 23 cycles of 94°C for 30 s, 56°C for 
30 s, and 72°C for 45 s, 94°C for 5 min, and one cycle of 72°C for 
10 min; for  StAR , one cycle of 94°C for 5 min, followed by 26 cycles 
of 94°C for 30 s, 50°C for 30 s, 72°C for 1 min, and one cycle of 
72°C for 10 min. The number of cycles was optimized for each 
gene to fall within the linear range of PCR amplifi cation. PCR 
products were resolved on a 1.5% agarose gel containing 0.5 µg/ml 
of ethidium bromide to determine the molecular sizes of the 
 Acsl4 ,  StAR , and  L19 amplicons. To compare the amounts of am-
plifi ed  Acsl4 and  StAR produced from different RNA samples, the 
amplifi ed  L19 product of each sample was used as an internal 
standard. The gel images were acquired with the GelPro analyzer 
(IPS). The levels of  Acsl4 ,  StAR , and  L19 mRNA were quantitated 
8382 (referred to as WT-SHP2 and CS-SHP2, respectively), were 
obtained from Addgene. CS-SHP2 is rendered catalytically inac-
tive by the C459S mutation in its catalytic site. Both forms were 
obtained in the pRC/CMV plasmid. The amplifi cation proce-
dure was verifi ed by nucleotide sequencing (Macrogen), and the 
obtained sequence was compared with that deposited in Gen-
bank [ Homo sapiens protein tyrosine phosphatase, nonreceptor 
type 11 (PTPN11), mRNA, accession number NM_002834]. 
 To obtain the knockdown plasmid, we used a 19-bp DNA frag-
ment of the mouse SHP2 (nucleotides 279-297) ( 33 ) in the ade-
quate frameshift to generate a short hairpin RNA (shRNA), 
which the cells process to generate a functional and active siRNA 
directed against the murine SHP2. A BLAST search confi rmed 
that the sequence specifi cally recognizes mouse SHP2. The insert 
was cloned in the pSUPER.retro.puro vector (Oligoengine). The 
obtained SHP2 shRNA construct was verifi ed by nucleotide se-
quencing (Macrogen), and the obtained sequence was compared 
with that deposited in Genbank [ Mus musculus protein tyrosine 
phosphatase, nonreceptor type 11 (Ptpn11), transcript variant 1, 
mRNA, accession number NM_011202]. Nontargeting control 
shRNA (named scrambled shRNA) consists of the same 19 nucle-
otides in a scrambled sequence, which does not target any known 
mouse cellular mRNA. 
 The knockdown of ACSL4 was performed with an already de-
scribed pSUPER.retro plasmid containing ACSL4 shRNA (nucle-
otides 1809-1827) ( 17 ). 
 Transfections 
 For transient transfections, MA-10 cells were cultured in 6-well 
plates (3.5-4 × 10 5 cells/well) overnight. The different constructions, 
WT-SHP2, CS-SHP2, SHP2 shRNA, scrambled shRNA, and ACSL4 
shRNA, and pRC/CMV and pSUPER.retro.puro as respective con-
trols, were transfected (4 µg DNA) using Lipofectamine 2000 re-
agent (Invitrogen) according to the manufacturer’s protocol. 
 Overexpression and knockdown effi ciency was confi rmed by 
Western blot analysis using specifi c antibodies against SHP2. 
Overexpression of endogenous SHP2, monitored by immuno-
blot analysis with anti-SHP2 antibody, was confi rmed in MA-10 
transfected with the mammalian expression vectors 24 h post-
transfection. Downregulation by shRNA occurred 48 h posttrans-
fection of the pSUPER-retro plasmid. 
 Transfection effi ciency for enhanced green fl uorescent pro-
tein (EGFP) ranged from 30 to 45%. Neither up- nor down-
expression of SHP2 affected cell viability, as assessed by the MTT 
assay. These results indicate that the transfection procedures do 
not affect mitochondrial function. Moreover, staining of the cells 
with the nuclear dye (DAPI) showed no change in nuclear mor-
phology, indicating that none of the treatments induced apopto-
sis in MA-10 cells (data not shown). 
 Cell treatments 
 MA-10 cells were pretreated with or without NSC87877 (50 µM) 
for 3 h and then incubated in the presence or absence of 
8Br-cAMP at the submaximal concentration of 0.5 mM for 1 h, 
with or without addition of AA (200 µM). Transfected MA-10 
cells were incubated in the presence or absence of 8Br-cAMP at 
the submaximal concentration of 0.5 mM for the indicated times 
(see fi gure legends), with or without addition of AA (200 µM). 
AA treatments were performed in serum-free medium with 1% 
BSA fatty acid-free for 30 min prior to the stimulation. At the end 
of all experiments, progesterone production was determined in 
the culture media by RIA ( 21 ). MDA-MB-231 was treated with or 
without addition of PAO (1 µM) or BPA-(AM 2 ) (0.25 mM) (cell 
permeant derivative of the PTP inhibitor BPA) or NSC87877 
(50 µM) for the indicated times (see fi gure legends). When ste-
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cell line ( Fig. 1A ).  NSC87877 also showed an inhibitory 
effect on ACSL4 protein levels ( Fig. 1A ), directly involving 
SHP2 in the induction of this acyl-CoA synthetase. Next, 
we measured the proliferation of MDA-MB-231 cells in the 
presence of NSC87877, which, because of the reduction in 
ACSL4 protein levels, should affect AA generation and 
metabolism. SHP2 inhibition with this compound resulted 
in a signifi cant decrease in the number of MDA-MB-231 
cells in the cultures at the end of the treatment, as deter-
mined by the MTT ( Fig. 1B ) and 8BrdU ( Fig. 1C ) assays. 
 We next used MA-10 Leydig cells to investigate the rela-
tionship between SHP2 and steroidogenesis. Cell cultures 
were treated with or without 8Br-cAMP (0.5 mM) in the 
presence or absence of NSC87877 (50 µM). ACSL4 pro-
tein level and progesterone production were determined 
under SHP2 inhibition. As previously described ( 11 ), we 
observed an increase in ACSL4 protein levels after the ac-
tion of 8Br-cAMP ( Fig. 1D ). The SHP2 inhibitor abolished 
the increase in ACSL4 protein levels ( Fig. 1D ). Regarding 
steroidogenesis, cAMP-stimulated progesterone produc-
tion was reduced by the use of NSC87877 ( Fig. 1E ). 
 To demonstrate that the effect of NSC87877 on ste-
roidogenesis is due to the reduction in ACSL4, we exoge-
nously added AA. We previously published that the 
cAMP-dependent signal transduction pathway activates 
tyrosine phosphatases upstream of ACSL4/Acot2 action 
( 18 ) ACSL4 is an enzyme involved in the generation and 
export of mitochondrial AA ( 11, 17, 42 ). ACSL4 converts 
AA into the CoA ester, which is then the substrate for 
Acot2, a mitochondrial thioesterase. Because of the se-
quential action of these two enzymes, there is a compart-
mentalized generation of AA ( 12, 13 ) and metabolism 
through the lipoxygenase pathway ( 17 ). Therefore, the 
addition of AA should by pass the inhibition of SHP2 on 
steroidogenesis. As was already known, AA increased ste-
roid production by itself and with cAMP ( 42 ). Together 
with NSC87877, AA blunted the inhibition exerted by 
NSC87877 on cAMP-stimulated progesterone production 
( Fig. 1E ). In conclusion, the result obtained with the exog-
enous addition of AA indicates that the inhibition ob-
served with NSC87877 reinforces the notion that SHP2 
would be acting on AA generation because of its inducing 
action on ACSL4. 
 Because we used cell lines, we questioned whether the 
observed effects also occurred in a primary cell culture. 
Thus, we tested the effect of SHP2 inhibition on Leydig 
cells by incubation of interstitial rat testis cells with 
NSC87877, followed by evaluation of ACSL4 protein level 
and testosterone production upon stimulation by 8Br-
cAMP. The 8Br-cAMP treatment caused an increase in 
ACSL4 protein levels ( Fig. 1F ) and testosterone produc-
tion ( Fig. 1G ), as expected. In the presence of the SHP2 
inhibitor, there were lower levels of ACSL4 protein and 
testosterone production after cAMP stimulation. These re-
sults confi rmed the conclusions we reached using cell lines 
and validated using MA-10 Leydig cells as experimental 
model throughout the study. 
 As previously reported, ACSL4 was detected as a duplet 
( 1, 17, 45, 46 ). This duplet may be seen in the three cell 
using a computer-assisted image analyzer (ImageQuant 5.2), and 
the PCR results for each sample were normalized by  L19 mRNA. 
 Cell proliferation assay 
 Cell proliferation was measured by the MTT and 5-bromo-2’-
deoxyuridine assays. 
 The MTT assay, based on MTT reduction by the mitochon-
drial diaphorase enzyme, is an index of mitochondrial integrity 
( 39 ). It was performed as previously described ( 17, 40 ). DNA syn-
thesis was monitored by a colorimetric immunoassay based on 
the measurement of 5-bromo-2’-deoxyuridine (BrdU) incorpora-
tion (BrdU cell proliferation ELISA kit, Roche Diagnostics). 
The assay was performed according to the manufacturer’s 
instructions. 
 [1- 14 C]AA incorporation and AA-CoA measurement 
 MA-10 cells were labeled using [ 14 C]AA following a previously 
described methodology ( 41 ) with minor modifi cations ( 42 ). 
Briefl y, [ 14 C]AA (New England Nuclear; specifi c activity 53.0 
mCi/mmol) was incorporated (0.5 µCi/ml in serum-free Way-
mouth MB/752 containing 0.5% essentially fatty acid-free BSA) 
during 3 h at 37°C. The cells were incubated in the presence or 
absence of 0.5 mM 8Br-cAMP for 1 h, and cell lysates were ob-
tained using a lysis buffer containing 20 mM Tris, pH 7.4, 0.5% 
Triton X-100, 1 mM EGTA, 1 mM EDTA, and 130 mM NaCl. 
Lipid extraction was performed twice with ethyl acetate (six vol-
umes of solvent per one volume of cellular fraction) and centrifu-
gation at 800  g for 5 min. The organic phase was discarded, and 
the [ 14 C]AA-CoA formation was evaluated by extraction from the 
aqueous phase as previously described ( 42, 43 ). 
 Statistical analysis 
 All experiments were run in duplicate and repeated at least 
three times. The reported data are means ± SEM of the three (or 
more) independent experiments. As appropriate, statistical analy-
sis was performed by Student  t -test (comparison of two data sets) 
or one-way ANOVA. The latter was followed by posttests if  P < 
0.05 by ANOVA, using the Instat software package from Graph-
Pad, Inc. 
 RESULTS 
 Effect of inhibition of SHP2 on ACSL4 protein levels and 
cell proliferation in MDA-MB-231 breast cancer cells and 
on ACSL4 protein levels and steroidogenesis in MA-10 
Leydig cells and testicular rat interstitial cells 
 To test whether SHP2 could be the PTP involved in the 
regulation of ACSL4 protein expression, we evaluated cell 
functions under SHP2 inhibition using NSC87877, a po-
tent inhibitor of this PTP ( 44 ). 
 MDA-MB-231 cells derive from a highly aggressive hu-
man breast tumor and express high levels of ACSL4 mRNA 
and protein ( 10, 17 ). We used MDA-MB-231 cells to inves-
tigate the relationship between SHP2 and ACSL4 and cell 
proliferation. We fi rst evaluated ACSL4 protein levels in 
cells where PTPs were inhibited. To this end, cell cultures 
were treated with or without PAO (1 µM), BPA-(AM 2 ) 
(0.25 mM), or NSC87877 (50 µM). While PAO and BPA 
act through two different mechanisms on all members of 
the PTP family, NSC87877 is a specifi c inhibitor of SHP2. 
The inhibition of PTPs with PAO or BPA reduced ACSL4 
































1940 Journal of Lipid Research Volume 52, 2011
 To analyze the effect of modifying SHP2 protein levels 
on the fi nal response of steroidogenic stimulation, we col-
lected media from cells transfected with the constructs 
described above and determined steroid secretion. Over-
expression of WT-SHP2 signifi cantly increased cAMP-
stimulated progesterone production compared with 
mock-transfected cells ( Fig. 2E ), whereas the expression 
of the catalytically inactive form caused a consistent and 
repeated slight decrease (but not statistically signifi cant) 
in cAMP-stimulated steroidogenesis. The effect could be 
attributed specifi cally to SHP2, as MA-10 cell cultures 
transfected with SHP2-targeting shRNA, which downex-
presses SHP2, signifi cantly decreased cAMP-stimulated 
progesterone production compared with empty vector or 
scrambled shRNA transfections ( Fig. 2F ). Because empty 
vector or scrambled shRNA-transfected cells exhibited 
similar SHP2 protein levels and basal and cAMP-stimu-
lated steroid production, both may be used as mock 
transfections. 
 Effect of overexpression and knockdown of SHP2 on 
ACSL4 expression in MA-10 Leydig cells 
 ACSL4 expression was analyzed in both conditions of 
SHP2 expression levels and the results are shown in  Fig. 3 . 
 Mock transfection shows the already known increase in 
ACSL4 protein level under cAMP stimulation. WT-SHP2 
overexpression resulted in a signifi cant increase in ACSL4 
protein levels as compared with mock-transfected cells, an 
effect potentiated by cAMP, while the levels of ACSL4 were 
unaffected by CS-SHP2 transfection. Furthermore, CS-
SHP2 overexpression blunted the effect of cAMP on 
ACSL4 protein expression ( Fig. 3A ). 
 The expression of ACSL4 was also analyzed in cells 
where the expression of SHP2 was down-regulated. The 
reduced expression of SHP2 resulted in a signifi cant de-
crease in the mRNA and protein levels of the synthetase 
( Fig. 3B–D ).  Acsl4 mRNA level was increased in MA-10 
Leydig cells treated with cAMP, an effect impaired by 
SHP2 shRNA ( Fig. 3B ). As in the previous experiment, 
cAMP increased ACSL4 protein expression in MA-10 Ley-
dig cells, whereas SHP2 knockdown by shRNA abolished 
the effect, compared with mock ( Fig. 3C ) or scrambled 
shRNA ( Fig. 3D ) transfections. The decrease in ACSL4 
protein levels in SHP2-down-regulated cells should also be 
refl ected on the synthetase activity. To determine the en-
dogenous activity of ACSL4, we measured AA-CoA produc-
tion in MA-10 cells labeled with [1- 14 C] AA. The cell 
cultures were labeled with radioactive AA, which, once in-
corporated, is the substrate of the endogenous ACSL4 that 
renders AA-CoA. The radioactive form of this derivative 
was determined after organic extraction. We reproduced 
the previously published stimulatory effect of cAMP on the 
content of the CoA derivative of AA ( 42 ), an effect im-
paired in SHP2-lacking cells ( Fig. 3E ). 
 We also analyzed the effect of SHP2 expression on 
ACOT2 protein levels, the second enzyme involved in AA 
generation ( 13 ). The results indicate that neither the over-
expression nor the silencing of SHP2 affected ACOT2 pro-
tein levels (data not shown). 
types used. However, the difference between the two bands 
is better seen in MDA-MB-231 cells ( Fig. 1A ) than in MA-10 
cells ( Fig. 1B ) or freshly isolated interstitial testis cells ( Fig. 
1F ), where the electrophoresis conditions have to be fi nely 
adjusted to evidence the double band. Both alternative 
splicing and posttranslational modifi cation mechanisms 
can explain the detection of a duplet by Western blots. The 
gene encoding ACLS4 shows alternative splicing ( 45, 46 ), 
and the protein is possibly acetylated. It was also suggested 
that the different mobility is due to proteolisis or posttrans-
lational modifi cations, such as N-glycosilation ( 46 ). 
 The results obtained with NSC87877 assured us that 
SHP2 could be one of the PTPs involved in the increase in 
ACSL4 protein levels. This fi rst approach encouraged us 
to further analyze the effect of the modifi cation of SHP2 
expression levels on the regulation of ACSL4 mRNA and/
or protein expression and function in one of the cell types, 
the steroidogenic MA-10 Leydig cells. For that purpose, we 
used constructions with sequences that either upregulate 
or downregulate the amount of the endogenous enzyme. 
 Overexpression and knockdown of SHP2 in MA-10 
Leydig cells 
 We fi rst overexpressed SHP2 in MA-10 cells by means of 
a transient transfection approach using a pRC/CMV plas-
mid containing WT- or CS-SHP2 cDNA. The transfection 
of these plasmids renders the wild-type and catalytically in-
active forms, respectively. Then, 24 h after transfection, 
SHP2 expression levels in basal and cAMP-stimulated con-
ditions were evaluated by Western blot in the cell lysates. 
As expected, in basal nonstimulated conditions, transfec-
tion of both SHP2 cDNAs increased the SHP2 protein sig-
nal compared with the endogenous expression ( Fig. 2A ).  
Transfected WT-SHP2 migrated at the expected molecu-
lar weight of 80 kDa in SDS-PAGE and showed conserved 
PTP activity as evidenced by in-gel PTP assays ( Fig. 2B ). A 
higher intensity of PTP activity in a band of 80 kDa was 
obtained in WT-SHP2-tranfected cells compared with the 
mock-transfected cells. Expectedly, cells overexpressing 
CS-SHP2 showed PTP activity levels comparable to those 
of mock-transfected cells ( Fig. 2B ). 
 Regarding the effect of cAMP on SHP2, neither the 
SHP2 protein level of mock-transfected cells nor that of 
WT- or CS-SHP2-transfected cells was affected by treat-
ment with cAMP ( Fig. 2A ). However, the stimulation of 
the cells with cAMP resulted in an increase in the enzy-
matic activity of an 80 kDa band in mock- and WT-SHP2-
transfected cells ( Fig. 2B ). Transfection with the WT form 
of SHP2 displayed a basal activity that could be further in-
creased by cAMP. 
 Next, we knocked down the expression of SHP2 using 
SHP2 shRNA. After transfection of SHP2 shRNA sequences, 
the effi cacy of SHP2 targeting siRNA was confi rmed by 
Western blot analysis ( Fig. 2C ) and in-gel PTP activity analy-
sis ( Fig. 2D ). As expected, expression of SHP2-targeting 
shRNA decreased the level of endogenous SHP2, compared 
with both, empty, or scrambled shRNA transfections ( Fig. 
2C ). A lower intensity of PTP activity in a band of 80 kDa 
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 Fig.  1. Inhibition of SHP2 in MDA-MB-231 breast cancer cells, MA-10 Leydig cells, and interstitial rat testis 
cells: effect on ACSL4 protein levels, cell proliferation, and steroidogenesis. A: MDA-MB-231 cells were 
treated with PTP inhibitors, BPA-(AM 2 ) (0.25 mM), PAO (1 µM), or NSC87877 (50 µM) for 24 h. Cells were 
collected and the cell lysate proteins were used to analyze ACSL4 expression by Western blot with specifi c 
antibodies. A representative immunoblot is shown. The approximate molecular mass of each immunoblot-
ted protein is indicated. Each experiment was performed three times with similar results. The integrated 
optical density of each band was quantitated, ACSL4 values were normalized against the corresponding  
 -tubulin band, and the results were expressed in arbitrary units (AU). The results are means ± SEM of three 
independent experiments.  a P  < 0.05;  b P <  0.01 versus control. B and C: MDA-MB-231 cells were treated with 
NSC87877 (50 µM) for 96 h. Cell proliferation was measured by the MTT (C) and BrdU incorporation (D) 
assays. Data represent means ± SEM of three independent experiments. B:  a P < 0.05 versus control. C:  a P < 
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shRNA-treated cells ( Fig. 5A ).  The effects of AA alone or 
together with cAMP on mock-transfected cells reproduced 
previously published results ( 42 ). 
 Finally, additional demonstration of a role for ACSL4 in 
SHP2-mediated effects was obtained from siRNA experi-
ments to knockdown ACSL4 expression in SHP2 overex-
pressing cells. Cotransfection of MA-10 Leydig cells with 
the plasmid that overexpresses the wild-type form of SHP2, 
together with a plasmid that silences ACSL4, exerted an 
inhibitory effect on cAMP-stimulated progesterone pro-
duction and ACSL4 protein levels ( Fig. 5B, C ). Progester-
one production by SHP2 overexpression in ACSL4-depleted 
cells was only partially inhibited, possibly due to incom-
plete knockdown of ACLSL4. The effect of an excessive 
expression of SHP2 could not be inhibited totally by the 
ACLS4 shRNA transfection. 
 DISCUSSION 
 The intracellular abundance of ACSL4 protein has been 
determined in physiological and pathological conditions, 
demonstrating changes under the action of several factors: 
fasting/feeding state ( 6 ), ACTH/cAMP ( 11, 47 ), and AA 
action ( 47 ), and transformation processes ( 9, 10, 16 ). The 
main fi nding of the present study is the identifi cation of 
SHP2 as a PTP involved in the regulation of the expression 
of this previously known AA-metabolizing enzyme in highly 
proliferative breast cancer cells and in steroidogenic dif-
ferentiated Leydig cells. This conclusion is based on two 
facts:  i ) overexpression and downregulation of SHP2 in a 
steroidogenic system such as MA-10 Leydig cells resulted 
in the upregulation and downregulation of ACSL4, re-
spectively, and  ii ) inhibition of SHP2 in a proliferative sys-
tem such as MDA-MD-231 breast cancer cells reduced 
ACSL4 expression. 
 The joint action of SHP2 and ACSL4 could regulate a 
physiological function such as steroid production or lead 
to a pathological process such as cell transformation. Reg-
ulation of ACSL4 might change the subcellular pools of 
AA and AA-CoA and thereby alter a broad range of cellular 
 Since the changes in ACSL4 protein levels and activity 
should be refl ected in downstream steps such as StAR pro-
tein induction, we next examined the effect of overexpres-
sion and knockdown of SHP2 on StAR protein. 
 Effect of overexpression and knockdown of SHP2 on 
StAR expression in MA-10 Leydig cells 
 As StAR abundance depends on both the induction 
of ACSL4 protein and the generation of AA ( 11 ), we 
continued analyzing StAR protein levels in SHP2 up- or 
downregulated MA-10 Leydig cells. The results are 
shown in  Fig. 4 .  The overexpression of WT-SHP2 signifi -
cantly increased the expression of basal StAR protein 
compared with mock-transfected cells ( Fig. 4A ). Treat-
ment with cAMP further increased the expression of 
StAR protein in the WT-SHP2-transfected cells. Overex-
pression of CS-SHP2 did not change StAR basal protein 
levels and impaired the stimulation produced by cAMP 
treatment. 
 Downregulation of SHP2 also modifi ed StAR expres-
sion. Regarding  StAR mRNA levels, StAR expression was 
increased in MA-10 Leydig cells treated with cAMP. This 
effect was impaired by SHP2 shRNA ( Fig. 4B ). Again, 
cAMP treatment of the cells caused a signifi cant increase 
in StAR protein levels in mock-transfected cells, whereas 
SHP2 shRNA treatment prevented the effect of cAMP on 
StAR protein in MA-10 cells ( Fig. 4C ). The involvement of 
AA in this process was reinforced by the fact that the AA 
addition to SHP2 shRNA-treated cells bypassed the inhibi-
tory effect described above ( Fig. 4C ). 
 Role of ACSL4 in SHP2-mediated effect on 
cAMP-stimulated steroidogenesis in MA-10 Leydig cells 
 There is a correlation between SHP2 and ACSL4 pro-
tein levels ( Fig. 3 ). As stated above ( Figs. 1E and 4C ) and 
according to previous publications, ACSL4 action in ste-
roidogenic cells directs AA to the compartamentalized 
metabolism through the lipoxygenase pathway. Thus, the 
observed inhibitory effect of SHP2 shRNA on steroido-
genesis should be bypassed by the addition of AA. Indeed, 
AA was able to restore the steroid production in SHP2 
stimulation was performed with or without 8Br-cAMP (0.5 mM) for 1 h. Cells were collected and the cell 
lysate proteins were used to analyze ACSL4 expression by Western blot with specifi c antibodies. A representa-
tive immunoblot is shown. The approximate molecular mass of each immunoblotted protein is indicated. 
Each experiment was performed three times with similar results. The integrated optical density of each band 
was quantitated, and ACSL4 values were normalized against the corresponding   -tubulin band and ex-
pressed as arbitrary units (AU). The results are means ± SEM of three independent experiments.  a P < 0.001 
versus cAMP alone. E: MA-10 Leydig cells were pretreated with or without NSC87877 (50 µM) for 3 h and 
then incubated in the presence or absence of AA (200 µM). The stimulation was performed with or without 
8Br-cAMP (0.5 mM) for 1 h. Steroid production was evaluated determining progesterone production in the 
culture media by radioimmunoassay. Data represent means ± SEM of fi ve independent experiments.  a P < 
0.001 versus cAMP alone;  b P < 0.05 versus cAMP + NSC87877. F, G: Interstitial testicular cells were pretreated 
with or without NSC87877 (50 µM) for 30 min. The stimulation was performed with or without 8Br-cAMP 
(0.5 mM) for 3 h. F: Cells were collected and the cell lysate proteins were used to analyze ACSL4 expression 
by Western blot with specifi c antibodies. A representative immunoblot is shown. The approximate molecular 
mass of each immunoblotted protein is indicated. Each experiment was performed three times with similar 
results. The integrated optical density of each band was quantitated, and ACSL4 values were normalized 
against the corresponding   -tubulin band and expressed as arbitrary units (AU). The results are means ± 
SEM of three independent experiments.  a P < 0.05 versus cAMP alone. G: Steroid production was evaluated 
determining testosterone production in the culture media by radioimmunoassay. Data represent means ± 
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 Fig.  2. Overexpression and knockdown of SHP2 in MA-10 Leydig cells: SHP2 protein levels, PTP activity, 
and steroid production. MA-10 cells were cultured and transiently transfected with an empty pRC/CMV 
(mock) or a pRC/CMV plasmid containing either a wild-type (WT-SHP2) or a catalytically inactive form (CS-
SHP2) of SHP2 for 24 h (A, B, E) or with an empty pSUPER.retro.puro vector (empty) or a pSUPER.retro.
puro vector containing scrambled shRNA (scr shRNA) or SHP2 shRNA (C, D, F) for 48 h. A and B: Cells 
were treated with or without 0.5 mM 8Br-cAMP for 1 h (A) or the indicated times (B). The cell lysates were 
used to analyze SHP2 protein levels by Western blot (A) or PTP activities by in-gel PTP assay (B). C and D: 
Cells were collected, and the cell lysate proteins were used to analyze SHP2 levels by Western blot (C) or PTP 
activity by in-gel PTP assay (D). A and C show representative immunoblots. The approximate molecular mass 
of each immunoblotted protein is indicated. Each experiment was performed three times with similar re-
sults. The integrated optical density of each band was quantitated. SHP2 values were normalized against the 
corresponding   -tubulin band and expressed as arbitrary units (AU). The results are means ± SEM of three 
independent experiments. A:  a P < 0.001 versus mock. C:  a P < 0.05 versus empty or scrambled shRNA contain-
ing vector. B and D show the autoradiography of a representative  32 P-poly (Glu:Tyr)-containing gel processed 
to develop PTP activity. Each experiment was performed three times with similar results. The integrated opti-
cal density of each band was quantitated. The values of the 80 kDa PTP activity are expressed as arbitrary 
units (AU). The results are means ± SEM of three independent experiments. B:  a P < 0.001 versus mock with-
out cAMP;  b P < 0.01 versus WT-SHP2 without cAMP. D:  a P < 0.05 versus mock. E and F: MA-10-transfected 
cells were incubated in serum-free medium in the presence or absence of 0.5 mM 8Br-cAMP for 1 h. Steroid 
production was evaluated by determining progesterone concentrations in the medium. Data are shown as 
progesterone concentration in nanograms per milliliter. The results are means ± SEM of four independent 
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 Fig.  3. Overexpression and knockdown of SHP2 in MA-10 Leydig cells: effect on ACSL4 expression and activ-
ity. MA-10 cells were cultured and transiently transfected with an empty pRC/CMV (mock) or a pRC/CMV 
plasmid containing either a wild-type (WT-SHP2) or a catalytically inactive form (CS-SHP2) of SHP2 for 24 h (A) 
or with an empty pSUPER.retro.puro vector (mock) or a pSUPER.retro.puro vector containing scrambled 
shRNA (scr shRNA) or SHP2 shRNA (B–E) for 48 h. A, C, and D: MA-10-transfected cells were incubated in se-
rum-free medium in the presence or absence of 0.5 mM 8Br-cAMP for 1 h. Cells were collected, and the cell 
lysate proteins were used to analyze ACSL4 expression by Western blot with specifi c antibodies. Representative 
immunoblots are shown, and the approximate molecular mass of each immunoblotted protein is indicated. 
Each experiment was performed three times with similar results. The integrated optical density of each band was 
quantitated. ACSL4 values were normalized against the corresponding   -tubulin band and expressed as arbi-
trary units (AU). The results are means ± SEM of three independent experiments. A:  a P < 0.01 versus mock;  b P < 
0.001 versus mock;  c P < 0.001 versus mock + cAMP;  d P < 0.05 versus WT-SHP2. C:  a P < 0.001 versus mock + cAMP. 
D:  a P < 0.01 versus scrambled shRNA + cAMP. B: MA-10-transfected cells were incubated in serum-free medium 
in the presence or absence of 0.5 mM 8Br-cAMP for 1 h. Total RNA was isolated and used in semiquantitative 
RT-PCR with specifi c primers for  Acsl4 cDNA and  L19 cDNA as loading control. PCR products were resolved in 
ethidium bromide-stained agarose gels. A representative gel is shown. Each experiment was performed three 
times with similar results. The integrated optical density of each band was quantitated.  Acsl4 values were normal-
ized against the corresponding  L19 band and expressed as arbitrary units (AU). The results are means ± SEM of 
three independent experiments.  a P < 0.01 versus mock + cAMP. E: MA-10-transfected cells were labeled with 
[ 14 C]AA as described in “Materials and Methods” and incubated in serum free-medium in the presence or ab-
sence of 0.5 mM 8Br-cAMP for 1 h. Cells were collected, and the cell lysates were used to analyze AA-CoA accu-
mulation by lipid extraction as described. The [ 14 C]AA-CoA content is expressed as means ± SEM of three 
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 Fig.  4. Overexpression and knockdown of SHP2 
in MA-10 Leydig cells: effect on StAR expression. 
MA-10 cells were cultured and transiently transfected 
with an empty pRC/CMV (mock) or a pRC/CMV 
plasmid containing either a wild-type (WT-SHP2) or 
a catalytically inactive form (CS-SHP2) of SHP2 for 
24 h (A) or with an empty pSUPER.retro.puro vec-
tor (mock) or a pSUPER.retro.puro vector contain-
ing SHP2 shRNA for 48 h (B and C). A and C: 
MA-10-transfected cells were incubated in serum-
free medium in the presence or absence of 0.5 mM 
8Br-cAMP for 2 h. In C, the cells were previously in-
cubated in the presence or absence of 200 µM AA. 
StAR protein levels were evaluated in the mitochon-
drial fraction by Western blot analysis. Representa-
tive immunoblots are shown, and the approximate 
molecular mass of each immunoblotted protein is 
indicated. Each experiment was performed three 
times with similar results. The integrated optical 
density of each band was quantitated. StAR values 
were normalized against the corresponding mito-
chondrial complex III bands and expressed as arbi-
trary units (AU). The results are means ± SEM of 
three independent experiments. A:  a P < 0.001 versus 
mock;  b P < 0.001 versus mock + cAMP;  c P < 0.05 ver-
sus WT-SHP2 alone. C:  a P < 0.001 versus mock + 
cAMP;  b P < 0.05 versus SHP2 shRNA + cAMP. B: MA-
10-transfected cells were incubated in serum-free 
medium in the presence or absence of 0.5 mM 8Br-
cAMP for 1 h. Total RNA was isolated and used in 
semiquantitative RT-PCR with specifi c primers for 
 StAR cDNA and  L19 cDNA as loading control. PCR 
products were resolved in ethidium bromide-stained 
agarose gels. A representative gel is shown. The inte-
grated optical density of each band was quantitated. 
 StAR values were normalized against the correspond-
ing  L19 band and expressed as arbitrary units (AU). 
The results are means ± SEM of three independent 
experiments.  a P < 0.01 versus mock + cAMP. 
processes that are controlled by this ratio. Here we report 
that changes in ACSL4 protein levels altered AA-mediated 
cell functions: steroidogenesis in MA-10 Leydig cells and 
proliferation in MDA-MD-231 cells. As a result of ACSL4 
upregulation, overexpression of SHP2 increased StAR 
protein in MA-10 Leydig cells. SHP2 has to be present and 
activated by a cAMP-dependent pathway as the overexpres-
sion of a catalytically inactive form of the enzyme (CS-
SHP2) did not reproduce the stimulatory effects of the 
wild-type form on ACSL4 protein levels, and it reduced 
cAMP action on steroidogenesis. Moreover, the catalyti-
cally inactive form slightly reduced the basal levels of pro-
gesterone production. This was probably due to an already 
described substrate-trapping action of the CS-SHP2 mu-
tant ( 48 ), which would reduce the action of the endoge-
nous enzyme. 
 The overexpression of the wild-type form of SHP2 in-
creased the levels of ACSL4 ( Fig. 3 ) and StAR ( Fig. 4 ) pro-
teins in nonstimulated MA-10 cultures. However, there 
was no stimulatory effect on the basal steroid production 
( Fig. 2 ). These results are in line with previous publica-
tions that indicate that steroidogenesis is dependent on 
the activity of PKA ( 49, 50 ) and on phosphorylation and 
activation of StAR by PKA ( 51 ) and ERK ( 52 ). The sole 
increase in SHP2 and ACSL4 levels was not enough to in-
crease steroid production because PKA and ERK activa-
tion are lacking. 
 The effects observed under overexpression of SHP2 
could be due to high levels of this PTP unspecifi cally re-
placing the function of another endogenous PTP. This 
possibility was ruled out using NSC87877, a specifi c in-
hibitor of SHP2, and the SHP2-specifi c shRNA. The re-
sults confi rmed the need for an endogenous SHP2 to 
regulate the levels of ACSL4 and StAR proteins and ste-
roidogenesis. This is the fi rst demonstration that SHP2 
upregulates the levels of ACSL4, the rate-limiting en-
zyme of the AA generation/export system in mitochon-
dria of steroidogenic cells. As AA is necessary for StAR 
protein induction and, fi nally, for steroidogenesis, this 
statement is reinforced by the fact that the effect of SHP2 
shRNA on StAR and steroidogenesis was overcome by ex-
ogenous addition of AA. We propose that SHP2-mediated 
production of progesterone involves ACSL4. Indeed, si-
lencing ACSL4 from MA-10 Leydig cells signifi cantly re-
duced progesterone production in response to cAMP. 
Progesterone production by SHP2 overexpression in 
ACSL4-depleted cells is partially inhibited, possibly due 
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 Fig.  5. Effect of AA on SHP2 shRNA inhibited steroidogenesis 
and effect of ACSL4 shRNA on WT- SHP2 stimulated steroidogen-
esis. MA-10 cells were cultured and transiently transfected with an 
empty pSUPER.retro.puro vector (mock) or a pSUPER.retro.puro 
vector containing SHP2 shRNA for 48 h (A) or cotransfected with 
a wild-type form of SHP2 (WT-SHP2) together with a pSUPER.
retro.puro vector containing ACSL4 shRNA for 48 h (B and C). 
MA-10-transfected cells were incubated in serum-free medium with 
(A) or without AA (B and C) in the presence or absence of 0.5 mM 
8Br-cAMP for 1 h. A and B: Steroid production was evaluated by 
determining progesterone concentrations in the medium. Data are 
shown as progesterone concentration in nanograms per milliliter. 
The results are means ± SEM of three (A) or six (B) independent 
experiments. C: Cells were collected, and the cell lysate proteins 
were used to analyze ACSL4 expression by Western blot with spe-
cifi c antibodies. Representative immunoblots are shown, and 
the approximate molecular mass of each immunoblotted protein 
is indicated. The experiment was performed three times with simi-
lar results. The integrated optical density of each band was 
quantitated. ACSL4 values were normalized against the corre-
sponding   -tubulin band and expressed as arbitrary units (AU). 
The results are means ± SEM of three independent experiments 
(C). A:  a P < 0.001 versus mock + cAMP;  b P < 0.05 versus SHP2 
shRNA + cAMP. B:  a P < 0.05 versus plasmids + cAMP;  b P < 0.01 ver-
sus plasmids + cAMP;  c P < 0.01 versus WT-SHP2 + cAMP. C:  a P < 
0.001 versus plasmids + cAMP;  b P < 0.05 versus plasmids + cAMP; 
 c P < 0.01 versus WT-SHP2 + cAMP. 
 
However, we cannot rule out that SHP2 is exerting its ac-
tions via alternative mechanisms. 
 Here we further demonstrated that SHP2 is activated 
through a cAMP-dependent pathway ( 24 ), evidenced by 
the increase in SHP2 activity after cAMP action in overex-
pression experiments. Our results are in agreement with 
the only report published on the subject. Rocchi et al. ( 24 ) 
described that SHP2 is phosphorylated in vitro by PKA and 
in vivo by ACTH in bovine adrenal cells. In both cases, 
phosphorylation increases SHP2 activity. Note that this 
previous report did not describe any physiological func-
tion of SHP2 nor did it evaluate the relationship of this 
modifi cation with the function. Thus, our report is the 
fi rst to show a relationship between cAMP-dependent acti-
vation of SHP2 and its functional role. We cannot state 
whether the activation is by direct or indirect PKA-depen-
dent phosphorylation of SHP2. 
 To our knowledge, this is also the fi rst report relating 
SHP2 to an arachidonic acid-metabolizing enzyme such as 
ACSL4. Although it is known that ACSL4 induction is reg-
ulated by a cAMP/PKA-dependent pathway ( 11 ) and by 
AA ( 47 ), we still do not know the mechanism by which 
SHP2 regulates ACSL4 induction in our system. It is pos-
sible to state that ACSL4 expression is regulated at tran-
scriptional and translational levels, depending on the 
length of cAMP action. At periods shorter than 1 h of 
cAMP action, ACSL4 protein levels are increased ( 11 ), 
and there is no action on mRNA levels (data not shown), 
indicating a regulation at the translational level. After 1 h of 
cAMP action, both protein ( Fig. 3C, D ) and mRNA ( Fig. 3B ) 
levels are increased, indicating that there is additional 
regulation at the transcriptional level. 
 The involvement of SHP2 in AA metabolism may ex-
plain its role in cell functions. SHP2 has been related to 
cell proliferation, survival, migration, and differentiation 
( 52, 53 ). With regard to the mammalian enzyme, stimula-
tory mutations of the human gene have been found re-
sponsible for several abnormalities, such as the pathological 
activity of Helicobacter pylori ( 54 ), Noonan syndrome 
( 33 ), leukemogenesis ( 55 ), and human breast cancer ( 56, 
57 ). Although the relationship between SHP2 and hor-
monal imbalance has been analyzed, particularly in diabe-
tes ( 58–60 ), the role of SHP2 in these disorders is not yet 
fully described or understood. Here we report a new physi-
ological role of SHP2 in hormone action, particularly in 
the hormonal activation of steroidogenesis. 
 Our identifi cation of SHP2 as an endogenous regulator 
for ACSL4 expression puts one more piece of the puzzle in 
place. It helps to identify the PTP involved and describes a 
































Involvement of a tyrosine phosphatase in ACSL4 expression 1947
enzyme such as ACSL4. Additionally, it provides an attrac-
tive target for the treatment of dysregulated cell growth. 
Studying the mechanism by which SHP2 exerts its action 
on ACSL4 induction remains a major challenge for future 
research.  
 The authors acknowledge Dr. Ben Neel for providing the WT- 
and CS- SHP2 pRC/CMV to Addgene. Thanks are also due to 
Carlos F Méndez and Cristina Paz for their critical reading of 
the manuscript. 
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